Transcriptomic Dissection of Bothrops moojeni Venom Reveals Fraction-Specific Modulation of Host Cellular Pathways
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27135943 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Fernanda D'Amélio und 4 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Program in Structural and Functional Biology, UNIFESP, São Paulo 04023-062, Brazil. Hauptthemen laut MEDLINE: Bothrops, Transcriptome, Crotalid Venoms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline (Canada), São Paulo Research Foundation.
Abstract (Originalsprache)
Snake venom is a remarkably complex cocktail of bioactive molecules capable of hijacking diverse host physiological processes, yet how individual venom components drive these cellular responses remains a bit of a black box. To map these dynamics, we ran a comparative transcriptomic analysis on human osteoclastogenic cultures, exposing them continuously to crude Bothrops moojeni venom and its high (HMM) and low (LMM) molecular mass fractions throughout differentiation. This allowed us to capture the cumulative transcriptional shifts that unfold across the entire lifecycle of osteoclast development. The crude venom triggered a sweeping response, deeply impacting neuroimmune, extracellular matrix remodeling, inflammatory, and apoptotic pathways—reflecting a massive reshuffling of cellular regulatory networks. When we looked at the fractions, clear dividing lines emerged. The HMM fraction, packed with metalloproteinases and serine proteases, mostly drove pathways tied to cytoskeletal remodeling, intracellular trafficking, and osteoclast-associated signaling. In contrast, the LMM fraction—home to phospholipases A2, disintegrins, and small peptides—steered a much more targeted course, influencing immune regulation, proliferative signaling, and metabolic homeostasis while noticeably turning down catalytic and binding functions. Interestingly, all venom-treated groups shared a drop-off in ATP-dependent and ligand-binding categories, pointing to a common disruption in core metabolic and signaling processes. Taken together, these findings offer a clearer mechanistic look at how different B. moojeni venom components target bone remodeling pathways, highlighting the power of transcriptomics for untangling complex venom–host interactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Postgraduate Program in Structural and Functional Biology, UNIFESP, São Paulo 04023-062, Brazil.
- Centre of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo 05503-900, Brazil.
- Laboratory of Genetics, Butantan Institute, São Paulo 05503-900, Brazil.
- BioDecision Analytics Ltd., São Paulo 01451-917, Brazil.
ORCID-Profile: Isabel de Fátima Correia Batista, Álvaro Rossan de Brandão Prieto-da-Silva
Förderung
- GlaxoSmithKline (Canada)
- São Paulo Research Foundation
Zitieren
APA
D'Amélio, F., Araldi, R. P., Batista, I. F. C., Prieto-da-Silva, Á. R. B., & Kerkis, I. (2026). Transcriptomic Dissection of Bothrops moojeni Venom Reveals Fraction-Specific Modulation of Host Cellular Pathways. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27135943
Vancouver
D'Amélio F, Araldi RP, Batista IFC, Prieto-da-Silva ÁRB, Kerkis I. Transcriptomic Dissection of Bothrops moojeni Venom Reveals Fraction-Specific Modulation of Host Cellular Pathways. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27135943
BibTeX
@article{DAmlio2026,
author = {D'Amélio, Fernanda and Araldi, Rodrigo Pinheiros and Batista, Isabel de Fátima Correia and Prieto-da-Silva, Álvaro Rossan de Brandão and Kerkis, Irina},
title = {Transcriptomic Dissection of Bothrops moojeni Venom Reveals Fraction-Specific Modulation of Host Cellular Pathways},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27135943}
}
EUVIMED